Clinical trial tests feasibility of targeting particular classes of tumor types with certain drugs

February 2, 2018 by Bob Yirka, Medical Xpress report
Credit: CC0 Public Domain

A large team of researchers from the U.S., Spain and Australia has found that the efficacy of drugs for treating cancer aimed at targeting particular classes of mutations depends on the type of tumor tissue involved and the nature of the mutations. In their paper published in Nature, the team describes the clinical trial and the results they have seen thus far. Elaine Mardis with the Institute for Genomic Medicine, Nationwide Children's Hospital, in Columbus, Ohio, offers a News & Views piece in the same journal issue outlining the study, and general research of abnormalities in genes linked to cancer and possible new treatment options.

In the past, doctors treated all patients with similar types of cancers in much the same way, but more recent research has shown this is not likely the best approach. This is because not all tumors for specific cancers are alike. As an example, not all lung tumors are the same—their cause and development can vary between patients. For this reason, scientists have been looking for ways to develop customized treatments based on an individual's circumstances. As this new approach has progressed, scientists have found that much of the difference between tumors can be traced back to differences in genes. In this new effort, the researchers have focused on mutations in the ERBB2 and ERBB3 genes because some of them have been found to overexpress HER2 proteins as part of .

To learn more about the role ERBB2 and ERBB3 play in development, the researchers gave a drug called neratinib to 141 patients with 21 types of cancer (and 42 kinds of mutations) in their clinical trial—it blocks the production of HER2 proteins. They have found that the effectiveness of the drug varied depending on mutational and tissue contexts. Some patients with ERBB2 mutations, they report, responded well to the drug, particularly those with tumors containing alterations in amino acids in extracellular or kinase HER2 domains. Others with tumors expressing HER2 proteins did not respond as well, and those with ERBB3 genes saw no change at all.

The researchers suggest their study has thus far shown that therapies designed to target certain classes of will have to take into account tumor tissue and the nature of the tumors involved.

Explore further: New statistical analysis reveals thousands of rare mutations linked with cancer

More information: David M. Hyman et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers, Nature (2018). DOI: 10.1038/nature25475

Abstract
Somatic mutations of ERBB2 and ERBB3 (which encode HER2 and HER3, respectively) are found in a wide range of cancers. Preclinical modelling suggests that a subset of these mutations lead to constitutive HER2 activation, but most remain biologically uncharacterized. Here we define the biological and therapeutic importance of known oncogenic HER2 and HER3 mutations and variants of unknown biological importance by conducting a multi-histology, genomically selected, 'basket' trial using the pan-HER kinase inhibitor neratinib (SUMMIT; clinicaltrials.gov identifier NCT01953926). Efficacy in HER2-mutant cancers varied as a function of both tumour type and mutant allele to a degree not predicted by preclinical models, with the greatest activity seen in breast, cervical and biliary cancers and with tumours that contain kinase domain missense mutations. This study demonstrates how a molecularly driven clinical trial can be used to refine our biological understanding of both characterized and new genomic alterations with potential broad applicability for advancing the paradigm of genome-driven oncology.

Related Stories

New statistical analysis reveals thousands of rare mutations linked with cancer

April 20, 2017
Scientists have identified thousands of previously ignored genetic mutations that, although rare, likely contribute to cancer growth. The findings, which could help pave the way to new treatments, are published in PLOS Computational ...

Investigators match novel cancer mutations with potential therapies

August 4, 2017
Research led by Vanderbilt-Ingram Cancer Center (VICC) investigators may have solved a mystery about why a targeted therapy stops working in a small group of breast cancer patients.

Study finds breast cancer driver, HER2, in 3 percent of lung cancers

July 27, 2017
The Lung Cancer Mutation Consortium at the University of Colorado Cancer Center reports this week in the journal Cancer that 24 of 920 patients (3 percent) with advanced-stage lung cancer had mutations in the gene HER2. Seventy-one ...

A new HER2 mutation, a clinical trial and a promising diagnostic tool for metastatic breast cancer

August 1, 2017
There is a group of metastatic breast cancers that has the HER2 gene amplified - the cells have many copies of it - which leads to enhanced activity of the product enzyme, a tyrosine kinase. HER2 has been established as a ...

Breast cancer cells found to switch molecular characteristics

August 24, 2016
A study led by Massachusetts General Hospital (MGH) investigators reveals how spontaneous changes in the molecular characteristics of tumors can lead to tumors with a mixed population of cells requiring treatment with several ...

Abnormalities in HER2 gene found in wide variety of advanced cancers

June 2, 2013
The HER2 growth-factor gene is known to be over-active in breast and gastro-esophageal cancers. But now, irregularities in the genes 's expression—among them mutations, amplifications, substitutions, and translocations—have ...

Recommended for you

Study tracks evolutionary transition to destructive cancer

February 23, 2018
Evolution describes how all living forms cope with challenges in their environment, as they struggle to persevere against formidable odds. Mutation and selective pressure—cornerstones of Darwin's theory—are the means ...

Researchers use a molecular Trojan horse to deliver chemotherapeutic drug to cancer cells

February 23, 2018
A research team at the University of California, Riverside has discovered a way for chemotherapy drug paclitaxel to target migrating, or circulating, cancer cells, which are responsible for the development of tumor metastases.

Lab-grown 'mini tumours' could personalise cancer treatment

February 23, 2018
Testing cancer drugs on miniature replicas of a patient's tumour could help doctors tailor treatment, according to new research.

An under-the-radar immune cell shows potential in fight against cancer

February 23, 2018
One of the rarest of immune cells, unknown to scientists a decade ago, might prove to be a potent weapon in stopping cancer from spreading in the body, according to new research from the University of British Columbia.

Putting black skin cancer to sleep—for good

February 22, 2018
An international research team has succeeded in stopping the growth of malignant melanoma by reactivating a protective mechanism that prevents tumor cells from dividing. The team used chemical agents to block the enzymes ...

Cancer risk associated with key epigenetic changes occurring through normal aging process

February 22, 2018
Some scientists have hypothesized that tumor-promoting changes in cells during cancer development—particularly an epigenetic change involving DNA methylation—arise from rogue cells escaping a natural cell deterioration ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.